Release no. 28/2012
Copenhagen and Oslo, 11th October 2012
NASDAQ OMX Copenhagen A/S has published the following today:
“On 7 September 2012 NASDAQ OMX Copenhagen A/S announced that Affitech A/S(ISIN DK0015966592, Orderbook ID 5017) will be deleted from trading and official listing as per 22 October 2012.
The exchange has decided to suspend the delisting of the company, because the Danish FSA has informed the exchange that the FSA will consider whether the exchange's decision to delete Affitech A/S is a violation of § 25 paragraph 3 of the Danish Securities Trading Act.
Thus, shares of Affitech A/S will be traded on NASDAQ OMX Copenhagen until further notice.
If the FSA agrees on the decision taken by the exchange, the delisting of Affitech A/S will take effect as soon as possible thereafter.”
The Board of Affitech A/S will consider the situation.
Randi Krogsgaard, Director IR & Communications
Tel # +45 2320 1001, e-mail: firstname.lastname@example.org
Stig Jarle Pettersen, CFO
Tel +47 9093 0336
Affitech A/S is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic antibody company based in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech’s premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS™. Further information is available at www.affitech.com.